Clinical effectiveness of parenteral trazodone for the management of psychomotor activation in patients with bipolar disorder by Ballerio, Martina et al.
To cite this article: Neuroendocrinol Lett 2018; 39(3):205–208
O
R
I
G
I
N
A
L
 
A
R
T
I
C
L
E
Neuroendocrinology Letters Volume 39 No. 3 2018
ISSN: 0172-780X; ISSN-L: 0172-780X; Electronic/Online ISSN: 2354-4716
Web of Knowledge / Web of Science: Neuroendocrinol Lett
Pub Med / Medline: Neuro Endocrinol Lett
This work is licensed under Creative Common Attribution-
NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0). 
No permission to resale without signed publisher agreement.
Clinical effectiveness of parenteral trazodone 
for the management of psychomotor 
activation in patients with bipolar disorder  
Martina Ballerio 1, Pierluigi Politi 1, Calogero Crapanzano 2, Enzo Emanuele 3, 
Alessandro Cuomo 2, Arianna Goracci 2, Andrea Fagiolini 2
1  Department of Brain and Behavioral Sciences, Section of Psychiatry, University of Pavia, Via Bassi, 
21, I-27100, Pavia, Italy
2  Department of Molecular Medicine and Clinical Department of Mental Health, University of Siena, 
Siena, Italy
3  2E Science, Robbio (PV), Italy
Correspondence to: Martina Ballerio, MD. 
Department of Brain and Behavioral Sciences, Section of Psychiatry, 
University of Pavia, Via Bassi, 21, I-27100, Pavia, Italy.
tel.: +39 0382 986437; fax.: +39 0382 502459; e-mail: m.ballerio@hotmail.it  
Submitted: 2018-05-14 Accepted: 2018-06-18 Published online: 2018-09-15
Key words:  Trazodone;  Parenteral route;  Psychomotor activation;  Bipolar disorder; 
 Retrospective study
Neuroendocrinol Lett 2018; 39(3):205–208 PMID: 30431739  NEL390318A06 © 2018 Neuroendocrinology Letters • www.nel.edu
Abstract OBJECTIVES: Trazodone is a multifunctional triazolopyridine drug with antide-
pressant, anxiolytic, sedative, and hypnotic properties. The current retrospective 
study was designed to investigate the effectiveness of trazodone for reducing acute 
psychomotor activation (PA) in patients with bipolar disorder (BD). We spe-
cifically reasoned that a parenteral route of administration could offer potential 
advantages in this clinical setting. 
METHODS: We assessed the effectiveness and safety of parenteral trazodone in 
a retrospective study conducted in 64 inpatients with BD and acute PA. The effec-
tiveness assessment was the Clinical Global Impression Scale − Severity Of Illness 
(CGI-S) rated before the administration of parenteral trazodone (baseline) and at 
the end of treatment. A post-treatment reduction in CGI-S score ≥ 20% compared 
with baseline was considered as the primary outcome measure. 
RESULTS: Administration of parenteral trazodone was associated with significant 
improvements in CGI-S scores from baseline (5.4 ± 0.9) to the end of the study (4.2 
± 1.0; p < 0.001, Wilcoxon matched-pairs signed-ranks test). A total of 34 patients 
(53.1%) showed a post-treatment reduction in CGI-S score ≥ 20% compared to 
baseline. Multivariable binary logistic regression analysis using a forward selec-
tion procedure identified treatment duration (in days) as the only independent 
predictor of post-treatment reduction in CGI-S score ≥ 20% (odds ratio: 1.28; 95% 
confidence interval: 1.02–1.60, p <0.05). Adverse effects occurred in 13 (20.3%) 
patients. 
CONCLUSIONS: Parenteral trazodone is well-tolerated and effective in 53.1% of 
patients with BP and acute PA. Treatment duration was identified as an indepen-
dent predictor of response in our sample. 
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INTRODUCTION
Psychomotor activation (PA) – defined as accelera-
tion, distractibility, hyperactivity, and restlessness – is 
common in patients with bipolar disorder (BD) and 
frequently accompanies noneuphoric hypomanic 
symptoms (Scott et al. 2017; Akiskal & Benazzi, 2005). 
Notably, a large multicenter study conducted in 1158 
patients has previously shown that PA is the most potent 
discriminator between unipolar and bipolar disorders 
(Cassano et al. 2012). From a clinical standpoint, PA 
is characterized by increased motor activity and pain-
ful inner tension that frequently represent a staggering 
challenge (Swann 2013). 
PA is an important therapeutic target in the acute 
and/or emergency setting, as well as for longer-term 
care of patients with BD (Scott et al. 2017). When inade-
quately managed, PA can result in an increased number 
and duration of inpatient hospital stays, a reduced like-
lihood of discharge to community and use of coercive 
measures and/or escalation to patient violence, present-
ing a substantial economic burden to the healthcare 
system (Scott et al. 2017; Akiskal & Benazzi, 2005). Oral 
antipsychotic agents given alone or in combination with 
benzodiazepines have been the preferred treatment of 
PA in patients with BD (Vieta 2008). However, while 
a preferred route of delivery in terms of maintaining a 
non-traumatic experience for the patient, orally dosed 
agents may not invariably be optimal in terms of deliv-
ering a sufficiently rapid onset of therapeutic effect 
(Buoli et al. 2017; Pallanti et al. 2002). In addition, the 
selection of a specific agent (or combination of agents) 
should be guided by etiologic considerations, efficacy 
of the drug(s), side effects, potential drug interactions, 
and drug formulation. 
Trazodone is a multifunctional triazolopyridine 
derivative characterized by a number of distinct phar-
macological actions (i.e., antidepressant, anxiolytic, 
sedative, and hypnotic) (Stahl 2009; Bossini et al. 2015). 
Trazodone may exert sedative actions by behaving as 
an antagonist of the serotonin 2A (5-HT2A) and 2C 
(5-HT2C) receptors, an antagonist of the alpha1 (α1) 
adrenergic receptors, and as an inhibitor of the H1 
histamine receptors (Stahl 2009; Bossini et al. 2015). 
In addition, it acts as a partial agonist of the the sero-
tonin 1A (5-HT1A) receptors, resulting in sedative and 
antidepressant effects (Odagaki et al. 2005). The latter 
action is nonetheless chiefly driven by the blockade of 
the serotonin transporter (SERT) (Stahl 2009; Fagiolini 
et al. 2012). Several studies have focused on the effec-
tiveness of trazodone in various patient populations 
(Bossini et al. 2012; Khouzam 2017; Mittur 2014); how-
ever, no data are currently available on its clinical utility 
for the treatment of acute PA in patients with BD. We 
therefore designed the current retrospective study to 
investigate the effectiveness of trazodone for reducing 
acute PA in patients with BD. We specifically reasoned 
that a parenteral route of administration could offer 
potential advantages (i.e., immediate achievement of 
an unsustained peak level in the bloodstream, complete 
bioavailability, and ensured compliance) in this clinical 
setting.
METHODS
Study sample and design
We assessed the effectiveness and safety of parenteral 
trazodone in a retrospective study conducted in 64 
inpatients with BD and acute PA (47 females and 17 
males, mean age: 52.2 ± 15.9 years). The subjects were 
recruited from the Division of Psychiatry, Univer-
sity of Siena, from December 2013 to March 2018 on 
the basis of specific inclusion and exclusion criteria. 
Patients who fulfilled the DSM-5 criteria (APA 2013) 
for BD were deemed eligible in presence of signs and 
symptoms of acute PA (acceleration, distractibility, 
hyperactivity, and restlessness) (Cassano et al. 2012). 
Patients were excluded when at least one of the follow-
ing conditions was met: 1) organic brain syndrome, 
2) schizophrenia, schizoaffective disorder, epilepsy, or 
any other neurological disorder; 3) imminent risk of 
causing injury to themselves or others; 4) suicidal risk 
as judged clinically; 5) serious or unstable medical ill-
nesses; 6) history of severe drug allergy or hyper-sensi-
tivity to trazodone; and 7) pregnancy or breastfeeding. 
Each case was recorded in detail on a specially designed 
proforma, which included the consent form and demo-
graphic data. The study medication is available as a 
parenteral preparation of 5 mL/vial containing 50 mg 
trazodone (Angelini, Rome, Italy). Parenteral trazodone 
was given either intravenously or intramuscularly with 
a flexible schedule, as permissible. Because no definite 
recommendations currently exist on the optimal route 
of administration for parental trazodone, intravenous 
or intramuscular injections were used at the physi-
cian’s discretion. The investigator also had the option to 
adjust the daily dose depending on individual patient’s 
response and/or presence of adverse effects. Concomi-
tant medications and adverse effects were recorded. 
Informed consent was waived because of the retrospec-
tive nature of the study and the analysis used anony-
mous clinical data. 
Study outcomes
The effectiveness assessment was the Clinical Global 
Impression Scale − Severity Of Illness (CGI-S) rated 
1) before the administration of parenteral trazodone 
(baseline) and 2) at the end of parenteral treatment. The 
CGI-S is a clinician-rated effectiveness measure of psy-
chopathology severity based on an 1 to 7 scale, as fol-
lows: 1 = normal, not at all ill; 2 = borderline mentally 
ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = 
severely ill; 7 = among the most extremely ill patients 
(Busner & Targum 2007). All patients had a CGI-S score 
≥4 at baseline. A post-treatment reduction in CGI-S 
score ≥ 20% compared with baseline was considered 
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as the primary outcome measure. The achievement of 
a post-treatment CGI-S score ≤ 3 served as a secondary 
outcome.
Data analysis
Continuous data are given as mean ± standard devia-
tion, whereas categorical data are expressed as counts 
(percentages). A Wilcoxon matched-pairs signed-ranks 
test was performed to compare baseline and post-treat-
ment CGI-S values. Multivariable binary logistic regres-
sion analysis with a forward selection procedure was 
used to identify the independent predictors of a post-
treatment reduction in CGI-S score ≥ 20% compared 
with baseline. The following covariates were entered 
into the multivariable model: age, sex, mean dosage of 
parenteral trazodone, route of patenteral administra-
tion (intravenous versus intramuscular), and duration 
of parenteral treatment (expressed in days). All calcula-
tions were performed using the SPSS software package, 
version 20.0 (IBM, Armonk, NY, USA). Two-tailed p
values <0.05 were considered statistically significant.
RESULTS
The mean dosage of parenteral trazodone adminis-
tered to the 64 study patients was 77.64 ± 38.69 mg/day 
(range: 25−250 mg/day) for an average of 3.89 ± 3.18 
days (range: 1−19 days). Trazodone was administered 
intravenously and intramuscularly in 39 (60.9%) and 
25 (39.1%) patients, respectively. Concomitant mood 
stabilizers, antipsychotic agents, benzodiazepines, 
gabapentin/pregabalin, and antidepressants were given 
to 55 (85.9%), 52 (81.3%), 49 (76.6%), 22 (34.4%), and 
17 (26.6%) patients, respectively. Administration of 
parenteral trazodone was associated with significant 
improvements in CGI-S scores from baseline (5.4 ± 0.9) 
to the end of the study (4.2 ± 1.0; p < 0.001, Wilcoxon 
matched-pairs signed-ranks test; Figure 1). A total of 34 
patients (53.1%) showed a post-treatment reduction in 
CGI-S score ≥ 20% compared to baseline in response to 
parental trazodone. Eighteen patients (28.1%) showed 
a CGI-S score ≤ 3 in response to parental trazodone. 
Multivariable binary logistic regression analysis using 
a forward selection procedure identified treatment 
duration (in days) as the only independent predictor 
of a post-treatment reduction in CGI-S score ≥ 20% 
(odds ratio: 1.28; 95% confidence interval: 1.02–1.60, p
<0.05). Adverse effects occurred in 13 (20.3%) patients, 
with the most frequent being sedation (n = 7, 10.9%), 
followed by orthostatic hypotension (n = 2 patients), 
dizziness (n = 2; 3.9%), nausea (n = 1; 1.5%), and oral 
paresthesia (n = 1; 1.5%). No patient discontinued par-
enteral treatment because of adverse effects.  
DISCUSSION
Serotonergic, adrenergic, and histaminergic neu-
rotrasmitter systems have been implicated in the 
pathogenesis of acute PA and may serve as therapeutic 
targets in the clinical management of this condition 
(Lindenmayer 2000; Munari et al. 2015). Trazodone is 
a multifunctional drug that offers unique therapeutic 
flexibility for a large number of comorbidities associ-
ated with mood disorders (Bossini et al. 2012; Mittur 
2011). As far as acute PA is concerned, trazodone may 
have therapeutic potential owing to its ability to inhibit 
H1 receptors along with simultaneous 5-HT2A and 
α1-adrenergic receptor antagonism (Stahl 2009). It was 
therefore reasonable to expect that trazodone might 
have a role in the treatment of PA in BP, with a lower 
burden of adverse drug events traditionally associated 
with oral antipsychotic agents (given alone or in combi-
nation with benzodiazepines). Herein, we demonstrated 
that 1) parenteral trazodone is well-tolerated and effec-
tive in 53.1% of patients with BP and acute PA and 2) 
treatment duration (in days) as the only independent 
predictor of a post-treatment reduction in CGI-S score 
≥ 20%.
The primary rationale for parenteral (versus oral) 
administration of trazodone is the immediate achieve-
ment of an unsustained peak level in the bloodstream 
(Stahl 2009; Nilsen & Dale 1992). This specific phar-
macokinetic profile is expected to induce a clinically 
significant hypnotic action not apparently accompanied 
by tolerance over time (Stahl 2009). Parenterally admin-
istered trazodone may also be instrumental in avoiding 
the hepatic first-pass effect, resulting in a complete bio-
availability and ensuring patient compliance (owing to 
the supervised drug administration) (Buoli et al. 2017; 
Berzewski 1988). Another interesting finding from our 
study is that the duration of treatment was identified 
as an independent predictor of the primary efficacy 
measure (the longer being the treatment duration, 
the higher the likelihood of CGI-S reduction). Albeit 
speculative, this phenomenon could be explained by 
Fig. 1. Observed changes in CGI-S scores from baseline to the end 
of the study in the 64 study patients.
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the 5-HT1A partial agonist action of trazodone (Oda-
gaki et al. 2005). Specifically, 5-HT1A agonist effects 
are believed to occur as a result of adaptive neuronal 
and receptor events occuring over time – and not by 
the acute engagement of the receptor per se (Odagaki 
et al. 2005; Settimo & Taylor 2018; Stahl 2013). Con-
sequently, the observed clinical effects of trazodone 
toward PA may on one side rely upon its immediate 
inhibition of H1 receptors along with simultaneous 
5-HT2A and α1-adrenergic receptor antagonism and 
– on the other side – upon longer-term modulation of 
5-HT1A receptor function. Our current observations 
may prompt further studies aimed at specifically inves-
tigating the optimal duration of parenteral trazodone in 
the clinical management of acute PA.
Our preliminary results need to be interpreted cau-
tiously given the small sample size, the retrospective 
nature of the study, the use of concomitant medications, 
the lack of blinded outcome ratings, and the absence 
of a placebo control group. These limitations notwith-
standing, our real-world data indicate that parenteral 
trazodone is well-tolerated and reasonably effective in 
the treatment of PA in BP. The current findings should 
be considered as exploratory and hypothesis-gener-
ating, warranting independent confirmation in well-
designed, adequately controlled ad hoc clinical trials.
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